Completed PHASE1 INTERVENTIONAL 2-arm NCT02206295

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

A Single-center, Open-label, Randomized, Two-period, Two-treatment, Crossover Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg (Reference Drug) or as Single Tablet of 1600 μg (Test Drug)

Sponsor: Actelion

Conditions Bioequivalence

Interventions selexipag

Updated 6 times since 2017 Last updated: Jan 31, 2025 Started: Sep 30, 2012 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02206295, this PHASE1 trial focuses on Bioequivalence and remains completed. Sponsored by Actelion, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Mar 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion

Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.